Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

45 results about "Mononuclear Blood Cell" patented technology

Kit for allogeneic peripheral blood mononuclear cell separation in vitro and application method of kit

The invention relates to a kit for high-purity high-recovery separation in vitro of allogeneic peripheral blood mononuclear cells and an application method of the kit. The allogeneic mononuclear cells separated by the kit can be used for immunotherapy of unexplained habitual abortion. The kit comprises a reagent I, namely a peripheral blood thinner, a reagent II, namely an erythrocyte sedimentation solution, a reagent III, namely mononuclear cell separating solution and a reagent IV, namely a mononuclear cell washing solution. The method for separating the allogeneic peripheral blood mononuclear cells by using the kit comprises the following steps: anticoagulation pre-centrifugation; erythrocyte initial reaction; erythrocyte sedimentation; two-step separation of the mononuclear cell separating solution; secondary purification of mononuclear cells; bacteria detection; mononuclear cell cryopreservation. According to the technology, the mononuclear cell recovery rate can achieve more than 90 percent, the purity can achieve more than 95 percent, the survival rate can achieve more than 98 percent, and the service efficiency of the peripheral blood mononuclear cells is greatly improved. Plasma is removed through the step of anticoagulation pre-centrifugation. Compared with the conventional separation technology, the dose of the separation reagent is reduced, and the separation cost is effectively reduced.
Owner:王盛

Application of peripheral blood mononuclear cells hsa-miR-8774-3p as marker of active tuberculosis

The invention relates to the technical field of biomarkers, in particular to application of a peripheral blood mononuclear cell hsa-miR-874-3p as a marker of active tuberculosis. The hsa-miR-874-3p issignificantly up-regulated in peripheral blood mononuclear cells from patients with active tuberculosis and a human monocyte cell line THP-1 infected with tuberculosis, and the up-regulated hsa-miR-874-3p possibly acts on ATG16L1 mRNA in mononuclear macrophages to regulate macrophage autophagy and participate in the infection process of Mtb. The up-regulated hsa-miR-874 has certain significance for the early diagnosis of APTB patients. The detection of the expression condition of hsa-miR-874 in patients with APTB using a qRT-PCR method can diagnose the disease. A new molecular target for clinical diagnosis and treatment is provided, and the development of new drugs is facilitated.
Owner:GUANGDONG MEDICAL UNIV

processing blood

Methods (300), devices, and systems of processing blood are describes. The method (300) comprises the steps of: obtaining (312) blood from a patient coupled to a single blood processing device to form a closed loop between the patient and the blood processing device; collection (314) bulk mononuclear blood cells from the blood by leukapheresis using the blood processing device in the closed loop; and enriching (316) concurrently target cells separated from non-target cells in the bulk mononuclear blood cells using the blood processing device in the closed loop.
Owner:THERAKOS INC

Method for separating and culturing peripheral blood mononuclear cells

The invention provides a method for separating and culturing peripheral blood mononuclear cells, and relates to the field of biotechnology cell culture. The separation and culture method of the peripheral blood mononuclear cells comprises the following steps: S1, collecting peripheral blood, S2, carrying out centrifugal separation, S3, extracting peripheral blood mononuclear cells, S4, purifying the peripheral blood mononuclear cells, S5, preparing a cell culture medium, S6, carrying out cell culture, and S7, performing preservation. An ALK inhibitor and a GSK-3 inhibitor are arranged, cytopathy in a cell culture process can be inhibited, excessive activation of pathological cells is prevented and rapid proliferation is carried out, animal serum is not added in the culture process, so thatthe possibility of obtaining viruses from animals in the culture process is reduced, the safety in the culture process is ensured, and peripheral blood mononuclear cells are cleaned and purified formultiple times after separation is completed, so that the cultured cells basically do not contain other impurity cells, and the cultured cells are relatively pure.
Owner:KUNMING MEDICAL UNIVERSITY

Method for preparing cord blood mononuclear cells

The invention provides a method for preparing cord blood mononuclear cells. The method comprises the following steps: (1) transferring collected cord blood into a sterile triple bag; (2) carrying outcentrifugal separation on the transferred cord blood; and (3) placing the centrifuged blood bag on a plasma separation clamp to remove plasma supernatant, and acquiring precipitate, namely a mononuclear cell preparation. The preparation method disclosed by the invention does not use hydroxyethyl starch and ficoll lymphocyte separation liquid, the prepared mononuclear cell preparation is safe and has no side effect, the recovery rate of mononuclear cells reaches more than 95%, and the cell activity is more than 93%. The invention also provides a cord blood mononuclear cell preparation. The preparation has small volume of just 10ml, and is convenient to infusion and use for newborn.
Owner:广州市天河诺亚生物工程有限公司

Separation method for separating peripheral blood mononuclear cells

The invention provides a separation method for separating peripheral blood mononuclear cells, and particularly relates to the field of biological medicines. The separation method comprises the following steps: S1, preparation of a separation tube: firstly, adding 2-6 ml of Percoll or polysucrose or meglumine diatrizoate cell separation liquid with the density of 1.075-1.0796 g/ml into a centrifugal tube, sucking 0.5-1.5 ml of separation gel with the density of 1.06-1.07 g/ml, adding the separation gel into a tube opening of the centrifugal tube, and carrying out horizontal centrifuging for 1-3minutes at room temperature under the centrifugal force of 800-1200 g, so that the separation gel forms an isolation layer on the liquid surface of the Percoll or polysucrose or meglumine diatrizoatecell separation liquid, and preparation of the separation tube is finished; and S2, separation of the peripheral blood mononuclear cells: adding 2-6 ml of anticoagulant whole blood into the preparedseparation tube, and carrying out horizontal centrifuging for 8-12 minutes at room temperature under the centrifugal force of 800-1200 g; sucking and discarding the uppermost liquid to remove cell fragments and platelets, directly pouring the liquid above the isolation layer into a collection tube, carrying out centrifuging for 4-6 minutes at room temperature under the centrifugal force of 600-1000 g, and resuspending the cells by using PBS to obtain the peripheral blood mononuclear cells. According to the separation method, it can be ensured that the anticoagulant whole blood can be absolutely not mixed with a cell separation medium after being added, and other cells are not polluted when the peripheral blood mononuclear cells are harvested.
Owner:JIANGSU TAIZHOU PEOPLES HOSPITAL +1

Sika deer specific CpG oligodeoxynucleotide and application thereof

The invention provides a sika deer specific CpG oligodeoxynucleotide and application thereof, and relates to the field of immunopotentiator for deer and vaccine adjuvant for deer. To boost the sika deer's immunity, the immune efficacy of sika deer vaccine and the antibody level of deer-derived bovine viral diarrhea / mucosal disease inactivated vaccine were increased, A CpG oligomeric deoxynucleotide specific to sika deer, As shown in SEQ ID NO. 3, A Chinese medicinal preparation is use for preparing immunopotentiator for sika deer, immunizing adjuvant for sika deer vaccine, and preparation of antiviral preparation against deer-derived bovine viral diarrhea / mucosal disease virus, and preparation of induce cells to produce antiviral substance against deer-derived bovine viral diarrhea / mucosaldisease virus, so as to improve antibody level of deer-derived bovine viral diarrhea / mucosal disease inactivated vaccine. As prove by experiments, that artificially synthesize sika deer specific CpGoligonucleotide can be used for sika deer peripheral blood mononuclear cells to exhibit antiviral activity, and at the same time, the deer-derived bovine viral diarrhea / mucosal disease inactivated vaccine immunity can be enhance. The sika deer specific CpG oligonucleotide can be used for sika deer peripheral blood mononuclear cells to show antiviral activity.
Owner:JILIN AGRICULTURAL UNIV

A CTL preparation method for efficient proliferation and targeted killing of tumors

The invention discloses an efficient multiplication CTL preparation method killing tumors in a targeted mode. The CTL preparation method comprises the following steps: (a) removing CD4+CD25+Treg cells through immunomagnetic bead negative sorting; (b) arranging mixed cells in a serum-free medium for cultivation, and obtaining suspension cells and adherent cells; (c) adding GM-SCF and IL-4 in the adherent cells, culturing the cells for five days; in the sixth day, adding a tumour cell holoantigen, and in the seventh day, adding TNF-alpha and IL-27; (d) transferring the suspension cells to a culture flask wrapped by a CD3 monoclonal antibody and recombinant human fibronectin, adding IFN-gamma, in the second day, adding IL-2, IL-12 and the IL-27, and culturing the mixture till the eighth day to obtain CIK cells; (e) mixing the CIK cells and mature DC cells, and adding the IL-12, IL-7 and an anti-CD 28 monoclonal antibody for cultivation; in the third day, adding an anti-CTLA-4 monoclonal antibody, and then culturing the mixture for four days. According to the efficient multiplication CTL preparation method killing tumors in the targeted mode, efficiency of in-vitro CTL cell proliferation is improved, activity of killing the tumor cells in the targeted mode is improved, transformation of peripheral blood mononuclear cells to the CD4+CD25+Treg cells is inhibited.
Owner:四川全组生命科技有限公司

NK cell culturing solutions and culturing method

The invention relates to the technical field of cell culturing, and particularly relates to an NK cell culturing solutions and culturing method. The invention discloses the NK cell culturing solutions, and the culturing solutions can perform compounding of IFN-gamma and IL-15 and perform compounding of IL-2, IL-1alpha and CD3 monoclonal antibodies, and based on combined effect, efficient transformation from peripheral blood mononuclear cells to NK cells is stimulated, the multiplying power of the NK cells is increased, and more NK cells are obtained, and moreover, contents of CD3-CD56+ and CD3+CD56+ are high, and the killing activity is high. The NK cell culturing solutions provided by the invention are illustrated that the toxic activity of the cells is obviously improved while the proliferation quantity of the NK cells is increased at the same time.
Owner:广州航华生物医药科技有限公司

Application of TLR7 and TLR8 as prophylactic and therapeutic targets for IgA nephropathy and inhibitors of TLR7 and their use

The invention relates to the technical field of biomedical technology, in particular to the application of TLR7 and TLR8 as prophylactic and therapeutic targets of IgA nephropathy and the applicationof inhibitor of TLR7 in prophylactic and therapeutic treatment of IgA nephropathy. The invention proves that the expression level of TLR7 gene and TLR8 gene in peripheral blood mononuclear cells (PBMCs) of IgA nephropathy patients is significantly increased compared with healthy control and disease control, when activated by TLR7 and TLR8 co-ligand R848, more IgA1 antibodies were produced, and abnormal O-glycosylation of the IgA1 antibodies were aggravated. Compounds of formula C<16>H<19>N<3>O<2> act as inhibitors of TLR7, inhibiting the ability of peripheral mononuclear blood cells to synthesize IgA1 and decreasing the abnormal O-glycosylation of these IgA1 molecules. Glycosylation. TLR7 and TLR8 are novel targets for the treatment of IgA nephropathy and have great clinical value.
Owner:THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products